Mr. Marcos Agramont reports

ISODIOL RECEIVES GOVERNMENT APPROVAL FOR PURE, NATURAL CBD AS AN ACTIVE PHARMACEUTICAL INGREDIENT

Isodiol International Inc.'s wholly owned subsidiary, BSPG Laboratories Ltd., has received government approval from United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA), in accordance with The Human Medicines Regulations 2012 (SI 2012/1916), for the manufacturing of the active substance cannabidiol (CBD) under certificate number: U.K. API 48727.

MHRA is an executive agency of the United Kingdom's Department of Health and is the regulatory agency that regulates medicines and medical devices. The MHRA is also a part of the European system of approval, where the MHRA or other national bodies can take on the verification work on behalf of all its members. Further, the MHRA is recognized globally as an authority in its field and plays a leading role in protecting and improving public health, and supports innovation through scientific research and development.

"This approval validates the consistent quality of our pure, natural CBD isolate and the patented manufacturing processes," said chief executive officer of Isodiol, Marcos Agramont. "This event is a first in the industry and now enables Isodiol to focus on the development of CBD based drugs that will address a myriad of conditions that are affecting so many people around the world. With this approval, we will now rapidly advance our pharmaceutical and drug development divisions."

With the MHRA approval and because it meets all legal requirements under international law, the company is now able to export the pure, natural CBD anywhere in the world, subject to pharmaceutical regulations. This approval sets Isodiol apart from all other CBD companies globally as a secure and reliable supplier positioned to be able to serve this newly created demand for CBD drug development, approved pharmaceutical applications, research, clinical studies and clinical trials. Upon completion of the company's new state-of-the-art manufacturing facility in Q1 2019, the company's production output capabilities will increase to approximately 20,000 kilograms of CBD -- API quality input material annually.

Dean Billington, qualified person, consultant of BSPG Laboratories Ltd., stated: "This is a huge achievement by BSPG laboratories and reflects the significant work and efforts made by the staff and management. The API registration also clearly demonstrates the commitment of BSPG Laboratories and Isodiol to manufacture the highest-quality CBD currently available worldwide."

About Isodiol International Inc.

Isodiol International is the market leader in pharmaceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99-per-cent-plus pure, bioactive pharmaceutical-grade cannabinoids, microencapsulations and nanotechnology for the highest-quality consumable and topical skin care products.

We seek Safe Harbor.